Hyperpolarized lactate contrast agent for determination of LDH activity

Patent metadata

Field	Value
Publication number	US-9408925-B2
Application number	US-201514979072-A
Country	US
Kind code	B2
Filing date	Dec 22, 2015
Priority date	May 3, 2010
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

A hyperpolarized MR imaging medium and a method of 13 C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarized [ 13 C, 2 H] lactate.

First claim

What is claimed is:

1. A method for determining LDH activity by 13 C-MR detection, wherein the method comprising:
using an imaging medium comprising hyperpolarised [ 13 C, 2 H] lactate; and
measuring the LDH-catalyzed exchange of deuterium label between the [ 13 C, 2 H] lactate and endogenous unlabelled lactate.

2. The method according to claim 1 , wherein the method is for in vivo determination of LDH activity in a human or non-human animal being.

3. The method according to claim 1 , wherein the method is for in vitro determination of LDH activity in a cell culture, in body samples, in ex vivo tissue or in an isolated organ derived from a human or non-human animal being.

4. The method according to claim 1 , further comprising using at least one signals to generate a map of the LDH activity.

5. The method according to claim 1 , further comprising:
using a heteronuclear 13 C/ 1 H spin echo imaging to monitor the LDH-catalyzed exchange of deuterium label between the [ 13 C, 2 H] lactate and the endogenous unlabelled lactate.

6. The method according to claim 1 , further comprising using a heteronuclear double echo imaging to monitor the LDH-catalyzed exchange of deuterium label between the [ 13 C, 2 H] lactate and the endogenous unlabelled lactate.

7. The method according to claim 1 , wherein the method is carried out in vivo or in vitro and wherein an information obtained by the method is used for at least one of:
assessing the efficacy of potential drugs that alter LDH activity, which includes lactate transport into the cell or endogenous lactate concentration;
assessing response to treatment and/or determining treatment efficacy in diseased patients undergoing treatment for their disease;
identifying patients at risk to develop a disease and/or candidates for preventive measures to avoid the development of a disease;
early detection of diseases;
monitoring progression of a disease;
determining the severity of a disease; and/or
identifying and assessing complications related to a disease.

Assignees

• Ge Healthcare Ltd
• Gen Electric

Inventors

• Brindle Kevin
• Kettunen Mikko
• Kennedy Brett

Classifications

• A61K49/10 Primary

  Organic compounds · CPC title

• C12Q1/32

  involving dehydrogenase · CPC title

• G01N33/60

  involving radioactive labelled substances · CPC title